Exagen (Exagen) Accounts Payable & Accrued Expense : $6.76 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Accounts Payable & Accrued Expense?

Exagen's quarterly accounts payable & accrued expense increased from Sep. 2023 ($7.88 Mil) to Dec. 2023 ($9.87 Mil) but then declined from Dec. 2023 ($9.87 Mil) to Mar. 2024 ($6.76 Mil).

Exagen's annual accounts payable & accrued expense declined from Dec. 2021 ($8.73 Mil) to Dec. 2022 ($7.25 Mil) but then increased from Dec. 2022 ($7.25 Mil) to Dec. 2023 ($9.87 Mil).

Exagen Accounts Payable & Accrued Expense Historical Data

The historical data trend for Exagen's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Accounts Payable & Accrued Expense Chart

Exagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.66

8.46

8.73

7.25

9.87

Exagen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															6.85	6.39	7.88	9.87	6.76

Exagen Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Exagen (Exagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

E08A:Germany

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Executives

John Aballi	director, officer: President and CEO	C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p.	10 percent owner	11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi	officer: Chief Financial Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine	officer: Chief Operating Officer	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson	director	800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L	director, 10 percent owner	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker	director	441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes	director	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack	officer: Chief Medical Officer	C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p.	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux	officer: Chief Scientific Officer	C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc	10 percent owner	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081